Open Access

Journal of Radiology

History of Endovascular Embolectomy for Emergent Large Vessel Occlusion

Simone Montoya

Department of Imaging Sciences, University of Rochester Medical Center, Imaging Sciences, 601 Elmwood Ave Box 648,
Rochester, NY, United States

Author :
Simone Montoya
Department of Imaging Sciences, University of Rochester Medical Center, Imaging Sciences, 601 Elmwood Ave Box 648,
Rochester, NY, United States

Received Date: Dec 31, 2022
Accepted Date: Jan 17, 2022
Published Date: Jan 27, 2023

Abstract

One of the main causes of morbidity and mortality in America as well as the main contributor to adult long-term impairment is acute ischemic stroke. Emergent causes of strokes. Large vascular occlusions (ELVO) frequently cause severe disability, but they can also be treatable with a chance for a successful functional outcome. The standard of care has changed significantly over a short period of time, moving from supportive care through systemic therapy and now to targeted therapy. Years of controversy surrounded the use of mechanical thrombectomy, but after five publications showing its superiority, it is now thought to be standard of care for patients who meet certain requirements. The goal of this essay is to provide the reader with an overview of the series of incidents that led to the current application of endovascular embolectomy in ELVO.

Keywords:
Embolectomy, thrombectomy, large vessel occlusion, stroke, stent retriever

Introduction

A stroke happens when the parenchyma of the brain has a disruption in blood flow, either because of a rupture (hemorrhagic stroke) or an obstruction (ischemic stroke). Ischemic stroke, which accounts for 87% of all strokes in the United States, is more frequent despite hemorrhagic stroke's higher associated mortality. [1] One of the leading causes of morbidity and mortality is acute ischemic stroke.worldwide, despite medical advancements. A new or recurrent stroke affects about 795,000 Americans annually, costing the country more than 70 billion dollars[1], and older patients fear a crippling stroke more than they fear dying. [2] The instrument that is most frequently used to evaluate functional outcome following a stroke is the modified Rankin Score (mRS, Table 1)[3]. The term "emergent large vessel occlusion" (ELVO) refers to the sudden blockage of a significant intracranial artery, most commonly the internal carotid artery (ICA), the M1 segment of the middle cerebral artery (MCA), or the basilar artery, which causes the majority of patients to experience long-term disability, which is generally characterised by mRS 2 in most studies.Tissue plasminogen activator-assisted systemic intravenous (IV) thrombolysis is the cornerstone of treatment for acute ischemic stroke (tPA). The tPA stroke research from the National Institute of Neurological Disorders and Stroke in 1995 showed theWhen a patient with a suspected stroke enters the emergency room (ED), it is important to ascertain whether

ASSESSMENT FOR ELIGIBILITY:

TREATMENT : When a patient with a suspected stroke arrives at the emergency room (ED), it is important to evaluate whether the patient is actually experiencing an acute ischemic stroke or if the neurological symptoms are caused by something else.

The majority (62%) of stroke mimics are caused by the following conditions: postictal state, systemic infection, malignancy, and toxic-metabolic disruption. [13] The Brain Attack Surveillance in Corpus Christi Project contrasted the first clinical stroke diagnosis made by ED doctors with a subsequent confirmation by board-certified neurologists and discovered that the sensitivity of the clinical diagnosis made by ED doctors was 92%.supporting the ED doctor's role in stroke screening and the neurologist's role in providing direction for treatment choices. [14] The sensitivity and specificity of clinical diagnosis in the ED were once more high (91.3% and 92.7%), according to a meta-analysis published in 2017. However, missed diagnoses were more frequent in several subgroups with milder, nonspecific, or transient symptoms at presentation. [15]

CONCLUSION :

In a short amount of time, the management of acute ischemic stroke, and particularly ELVO, has undergone a significant evolution. 2015 represented a turning point in the management of ELVO-induced acute ischemic stroke. In response to the MR CLEAN findings, ESCAPE, EXTEND IA, SWIFT PRIME, and REVASCAT were all terminated early due to efficacy thresholds being exceeded;[43–46] all five studies showed endovascular embolectomy to be beneficial and were reported concurrently. Additionally, none of these studies were published in industry-specific journals; instead, they were all covered inin the New England Journal of Medicine, a publication read by professionals from all specialties and having the greatest impact factor of any medical journal. Even before all of the trials were published, AHA/

ASA and SINS responded by issuing revised guidelines for the use of endovascular therapy for ELVO[7,9].

Endovascular intervention is recommended within 6 hours of the onset of symptoms, although many stroke patients appear outside of this window because they delayed going to a stroke centre or because the precise time of symptom onset is unknown. People who are discovered to have stroke symptoms (an "unwitnessed stroke") or who awaken from sleep with stroke symptoms (a "wake-up stroke") fall into the latter category.The European Stroke Organization heard the findings of the DAWN study, which used diffusion weighted imaging or CTP assessment with clinical mismatch in the triage of awake and late-presenting strokes requiring neurointervention.

REFERENCES :

1. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M,Das SR, Deo R, et al. Heart disease and stroke statistics-2017 update: A report from the American heart association. Circulation 2017;135:e146-603.

2. Solomon NA, Glick HA, Russo CJ, Lee J, Schulman KA.Patient preferences for stroke outcomes. Stroke1994;25:1721-5.

3. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ,van Gijn J. Interobserver agreement for the assessmentof handicap in stroke patients. Stroke 1988;19:604-7.

4. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 995;333:1581-7.

5. Marsh JD, Keyrouz SG. Stroke prevention and treatment. J Am Coll Cardiol 2010;56:683-91.

6. Marler JR, Tilley BC, Lu M, Brott TG, Lyden PC,Grotta JC, et al. Early stroke treatment associated with better outcome: The NINDS rt-PA stroke study. Neurology000;55:1649-55.

7. Powers WJ, Derdeyn CP, Biller J, Coffey CS, Hoh BL, Jauch EC, et al. American heart association/American stroke association focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: A guideline for healthcare professionals from the American heart association/American stroke association. Stroke 2015;46:3020-35.

8. Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, Fugate JE, Grotta JC, et al. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: A statement for healthcare professionals from the American heart association/american stroke association.Stroke 2016;47:581-641.

9. Jayaraman MV, Hussain MS, Abruzzo T, Albani B, Albuquerque FC, Alexander MJ, et al. Embolectomy for stroke with emergent large vessel occlusion (ELVO): Report of the standards and guidelines committee of the society of neurointerventional surgery. J Neurointerv Surg 2015;7:316-21.

10. Harbison J, Hossain O, Jenkinson D, Davis J, Louw SJ,Ford GA. Diagnostic accuracy of stroke referrals from primary care, emergency room physicians, and ambulance staff using the face arm speech test. Stroke 2003;34:71-6.

11. Gorelick PB. Primary and comprehensive stroke centers: History, value and certification criteria. J Stroke 2013;15:78-89.

12. Southerland AM, Johnston KC, Molina CA, Selim MH, Kamal N, Goyal M. Suspected large vessel occlusion:Should emergency medical services transport to the nearest primary stroke center or bypass to a comprehensive stroke center with endovascular capabilities? Stroke 2016;47:1965-7.

13. Libman RB, Wirkowski E, Alvir J, Rao TH. Conditions that mimic stroke in the emergency department.Implications for acute stroke trials. Arch Neurol 1995;52:1119-22.

14. Morgenstern LB, Lisabeth LD, Mecozzi AC, Smith MA,Longwell PJ, McFarling DA, et al. A population-based study of acute stroke and TIA diagnosis. Neurology 2004;62:895-900.

15. Tarnutzer AA, Lee SH, Robinson KA, Wang Z, Edlow JA,Newman-Toker DE. ED misdiagnosis of cerebrovascularevents in the era of modern neuroimaging: A metaanalysis. Neurology 2017;88:1468-77.

20. 16. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ.Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare

21. professionals from the American heart association/American stroke association. Stroke 2013;44:870-947.

22. 17. Fink JN, Selim MH, Kumar S, Silver B, Linfante I,Caplan LR, et al. Is the association of national institutes of health stroke scale scores and acute magnetic resonance imaging stroke volume equal for patients with right- and left-hemisphere ischemic stroke? Stroke 2002;33:954-8.

18. Moulin T, Cattin F, Crépin-Leblond T, Tatu L, Chavot D,Piotin M, et al. Early CT signs in acute middle cerebral artery infarction: Predictive value for subsequent infarct locations and outcome. Neurology 1996;47:366-75.

19. Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS study group. Alberta stroke programme early CT score. Lancet 2000;355:1670-4.

20. Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J,

et al. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke 2003;34:e109-37.

21. Fugate JE, Klunder AM, Kallmes DF. What is meant by 'TICI'? AJNR Am J Neuroradiol 2013;34:1792-7.

22. Zaidat OO, Yoo AJ, Khatri P, Tomsick TA, vonmKummer R, Saver JL, et al. Recommendations on angiographic revascularization grading standards for acute ischemic stroke: A consensus statement. Stroke 2013;44:2650-63.

23. del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in acute cerebral thromboembolism. Stroke 1998;29:4-11.

24. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study:A randomized controlled trial. Prolyse in acute cerebral thromboembolism. JAMA 1999;282:2003-11.

25. Ciccone A, Valvassori L, Nichelatti M, Sgoifo A,Ponzio M, Sterzi R, et al. Endovascular treatment for acute ischemic stroke. N Engl J Med 2013;368:904-13.

26. Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS,Gobin YP, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: Results of the MERCI trial. Stroke 2005;36:1432-8.

27. Becker KJ, Brott TG. Approval of the MERCI clot retriever: A critical view. Stroke 2005;36:400-3.

28. Saver JL. Time is brain-quantified. Stroke 2006;37:263-6.

29. Kidwell CS, Jahan R, Gornbein J, Alger JR, Nenov V,Ajani Z, et al. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med 2013;368:914-23.

30. Broderick JP, Palesch YY, Demchuk AM, Yeatts SD,Khatri P, Hill MD, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 2013;368:893-903.

31. Alexandrov AV, Demchuk AM, Burgin WS,Robinson DJ, Grotta JC; CLOTBUST Investigators.Ultrasound-enhanced thrombolysis for acute ischemic stroke: Phase I. Findings of the CLOTBUST trial.J Neuroimaging 2004;14:113-7.

32. Marks MP, Olivot JM, Kemp S, Lansberg MG,Bammer R, Wechsler LR, et al. Patients with acute stroke treated with intravenous tPA 3-6 hours after stroke onset: Correlations between MR angiography findings and perfusion- and diffusion-weighted imaging in the DEFUSE study. Radiology 2008;249:614-23.

33. Tomsick TA, Khatri P, Jovin T, Demaerschalk B,Malisch T, Demchuk A, et al. Equipoise among recanalization strategies. Neurology 2010;74:1069-76.

34. Ryu CW. A myth debunked: The results of synthesis expansion and IMS III. Neurointervention 2013;8:1-2.

35. Parsons MW, Albers GW. MR RESCUE: Is the glass half-full or half-empty? Stroke 2013;44:2055-7.

36. Lansberg MG, Straka M, Kemp S, Mlynash M,Wechsler LR, Jovin TG, et al. MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): A prospective cohort study. Lancet Neurol 2012;11:860-7.

37. Nagakane Y, Christensen S, Brekenfeld C, Ma H,Churilov L, Parsons MW, et al. EPITHET: Positive result after reanalysis using baseline diffusion-weighted imaging/perfusion-weighted imaging co-registration.Stroke 2011;42:59-64.

38. Kidwell CS, Alger JR, Saver JL. Beyond mismatch:Evolving paradigms in imaging the ischemic penumbra with multimodal magnetic resonance imaging. Stroke 2003;34:2729-35.

39. Saver JL, Jahan R, Levy EI, Jovin TG, Baxter B, Nogueira RG, et al. Solitaire flow restoration device versus the merci retriever in patients with acute ischaemicb stroke (SWIFT): A randomised, parallel-group, noninferiority trial. Lancet 2012;380:1241-9.

40. Jansen O, Macho JM, Killer-Oberpfalzer M, Liebeskind D, Wahlgren N; TREVO Study Group.Neurothrombectomy for the treatment of acute ischemic stroke: Results from the TREVO study. Cerebrovasc Dis 2013;36:218-25.

41. Nogueira RG, Lutsep HL, Gupta R, Jovin TG,Albers GW, Walker GA, et al. Trevo versus merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2):A randomised trial. Lancet 2012;380:1231-40.

42. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al. A randomized trial of intraarterial treatment for acute ischemic stroke.
N Engl J Med 2015;372:11-20.

43. Goyal M, Demchuk AM, Menon BK, Eesa M,Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015;372:1019-30.

44. Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM,Churilov L, Yassi N, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 2015;372:1009-18.

45. Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI,Pereira VM, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med

2015;372:2285-95.

46. Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med 2015;372:2296-306.

47. Saver JL, Goyal M, van der Lugt A, Menon BK, Majoie CB, Dippel DW, et al. Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke: A meta-analysis. JAMA 2016;316:1279-88.

48. Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: A meta-analysis of individual patient data from five randomised trials. Lancet 2016;387:1723-31.

49. Jovin TG, Nogueira RG. DAWN in Full Daylight: DWI or CTP Assessment with Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing
Neurointervention with Trevo. Presented at: 3rd European Stroke Organisation Conference (ESOC 2017). May, 16.Prague, Czech Republic; 2017.

50. Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3 (DEFUSE 3). NIH Stroke Net. Available from: https://www.nihstrokenet.org/clinical-trials/acute-interventional-trials/defuse-3.